CH

Linux Foundation Decentralized Trust Launches with 17 Projects, 100+ Founding Members

Retrieved on: 
Monday, September 16, 2024

SAN FRANCISCO and VIENNA, Sept. 16, 2024 /PRNewswire/ -- Today, to provide a neutral home for collaborative development of technologies powering the transition to a digital-first economy, the Linux Foundation formally launched Linux Foundation Decentralized Trust (LF Decentralized Trust), the premier open source foundation for decentralized technology ecosystems. Supported by more than 100 founding members, LF Decentralized Trust is a new umbrella organization that fosters collaboration and innovation across a growing ecosystem of blockchain, ledger, identity, interoperability, cryptographic, and related technologies. 

Key Points: 
  • SAN FRANCISCO and VIENNA, Sept. 16, 2024 /PRNewswire/ -- Today, to provide a neutral home for collaborative development of technologies powering the transition to a digital-first economy, the Linux Foundation formally launched Linux Foundation Decentralized Trust (LF Decentralized Trust), the premier open source foundation for decentralized technology ecosystems.
  • LF Decentralized Trust builds on more than eight years of work from across the Linux Foundation, including leading global blockchain and digital identity open source and standards projects.
  • With additional new ledger, consensus, and cryptography code contributions, LF Decentralized Trust is launching with 17 total projects.
  • "Around the world, decentralized technologies are modernizing critical systems and core infrastructure," said Daniela Barbosa, General Manager of Decentralized Technologies at the Linux Foundation and Executive Director of LF Decentralized Trust.

WISeKey Subsidiary WISe.Art Updates on Tokenization Project and Announces Marketplace Revamp

Retrieved on: 
Friday, September 13, 2024

At the core of this tokenization initiative is the revamp of the its WISe.Art Marketplace, a platform developed to redefine the art world by fostering transparency, security, authenticity, legal certainty, and fractional ownership, and transform the way art is bought and sold globally.

Key Points: 
  • At the core of this tokenization initiative is the revamp of the its WISe.Art Marketplace, a platform developed to redefine the art world by fostering transparency, security, authenticity, legal certainty, and fractional ownership, and transform the way art is bought and sold globally.
  • WISe.Art is making major investments in cutting-edge technology to overhaul the existing platform’s user interface (UI) and user experience (UX).
  • Carlos Moreira, CEO of WISeKey, commented on the project, “Tokenizing art assets through our WISe.Art Platform represents a significant milestone in our ongoing technological evolution.
  • With the upcoming revamp of our marketplace, we are investing heavily in technology to ensure that our platform remains at the forefront of security, innovation, and user experience.

ICP Hosts Chain Fusion Hub @ Token2049, Leading Discussions on AI, Web3 & Interoperability

Retrieved on: 
Friday, September 13, 2024

SINGAPORE, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Internet Computer Protocol (ICP), a decentralized blockchain technology network, has announced today that they are hosting Chain Fusion Hub @ Token2049, an exclusive events marathon, set to take place on September 19 and 20, between 10:00 and 19:00 UTC+8 at The Fullerton Hotel Singapore, an iconic neo-classical landmark of the city-state.

Key Points: 
  • Chain Fusion Hub takes place during Token2049 Singapore and Asia Crypto Week, ahead of Formula 1 Singapore Grand Prix 2024.
  • Chain Fusion Hub is a global event series on a mission to create the interoperable Web3 future and uniquely designed to bring together the strongest builders from across different chains.
  • Over the two days, ICP hosts a series of events alongside partners, with the event attracting some of the leading figureheads, institutions and projects in the space.
  • According to ICP, “Chain Fusion Hub is a sounding board for important conversations in the cross-chain and interoperability space.

Freename Integrates with Sei: Bringing Web3 Domains to the Sei Community

Retrieved on: 
Thursday, September 12, 2024

Zürich, Switzerland , Sept. 12, 2024 (GLOBE NEWSWIRE) -- Freename , a leading provider of multichain Web3 domains, announces its integration with the Sei blockchain.

Key Points: 
  • Zürich, Switzerland , Sept. 12, 2024 (GLOBE NEWSWIRE) -- Freename , a leading provider of multichain Web3 domains, announces its integration with the Sei blockchain.
  • This integration strengthens Freename’s goal of making Web3 domains more accessible and secure for users across multiple blockchain networks.
  • Freename's integration with Sei highlights the company's ongoing effort to expand the use of Web3 domains.
  • "This integration enhances Freename’s multichain offerings and provides our users with a dependable option for minting and managing Web3 domains.

21Shares Selects Anchorage Digital Bank and BitGo as Custodians for US Spot ETP Product Lineup

Retrieved on: 
Thursday, September 12, 2024

Anchorage Digital Bank and BitGo join current custodian Coinbase, strengthening 21Shares’ spot ETP operations in the US market.

Key Points: 
  • Anchorage Digital Bank and BitGo join current custodian Coinbase, strengthening 21Shares’ spot ETP operations in the US market.
  • 21Shares selected both Anchorage Digital Bank and BitGo due to their track records in regulatory compliance, safety and security.
  • “21Shares is thrilled to be working with Anchorage Digital Bank and BitGo to diversify our custodians for our US spot ETPs.
  • “Both Anchorage Digital Bank and BitGo are well established providers and will provide enhanced security to clients of ARKB and CETH.”
    Commenting on today’s announcement, Nathan McCauley, Co-Founder and CEO of Anchorage Digital Bank said: “Anchorage Digital Bank N.A.

Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, September 12, 2024

53 LR

Key Points: 
  • 53 LR
    A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
  • In March 2024, Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), executed the U.S. commercial launch of AGAMREE and reported yielding solid results and surpassing initial expectations by the end of June 2024.
  • In Germany, considering that Santhera launched AGAMREE on January 15, 2024, the pricing negotiations are expected to be concluded by January 15, 2025.
  • Once the agreed threshold or duration of royalty payments is met, the North America and China royalty payments will revert back to Santhera.

WISeKey’s SEALCOIN Project Leverages Hedera DLT: Invites IoT Companies to Perform Proof of Concept (PoC) for Transactional-IoT (t-IoT) Technology

Retrieved on: 
Wednesday, September 11, 2024

The result is a streamlined process that enhances efficiency, reduces costs, and creates a more seamless IoT ecosystem.

Key Points: 
  • The result is a streamlined process that enhances efficiency, reduces costs, and creates a more seamless IoT ecosystem.
  • At the core of this PoC is the use of cutting-edge technology embedded within semiconductor devices, which autonomously validates and verifies transactions.
  • SEALCOIN features a Secure Element—an embedded security hardware that protects the private key and certificate representing each device’s unique identity.
  • Earlier this year, WISeKey established SEALCOIN AG, a Special Purpose Vehicle (SPV), to house and advance the SEALCOIN decentralized technology project.

Bioversys Announces Strategic Investment From GIBF2 and Launch of BV100 Clinical Program in China

Retrieved on: 
Wednesday, September 11, 2024

The investment aligns with BioVersys’ strategic decision to expand the clinical development of its lead asset BV100 in China, to address a large unmet medical need affecting a very large patient population and offering a significant market opportunity.

Key Points: 
  • The investment aligns with BioVersys’ strategic decision to expand the clinical development of its lead asset BV100 in China, to address a large unmet medical need affecting a very large patient population and offering a significant market opportunity.
  • GIBF’s support for clinical trials and its extensive network in China are expected to facilitate and accelerate the clinical development of BV100.
  • Onboarding China to BioVersys’ planned global Phase 3 clinical trial first requires a small Phase 1 study in healthy volunteers to confirm the safety and pharmacokinetic profile of BV100 in the Chinese population.
  • We look forward to supporting BioVersys in its efforts to develop innovative anti-infective treatments in China."

WISeKey’s WISe.ART, Digital Platform Powered with Cyber Security, and CryptoVerse Island, Announce Their Support for the Maiti Nepal Foundation

Retrieved on: 
Tuesday, September 10, 2024

WISe.ART, which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, will participate in the Digital Art Day at the Carmen Bornemisza Thyssen Foundation in Malaga in the presence of Georg Bak of Art Meta.

Key Points: 
  • WISe.ART, which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, will participate in the Digital Art Day at the Carmen Bornemisza Thyssen Foundation in Malaga in the presence of Georg Bak of Art Meta.
  • Maiti Foundation currently sponsors twenty-one students to pursue higher secondary degree once graduated from Teresa Academy.
  • Each of the specially selected NFTs bought from the WISe.ART platform on this occasion will provide one full term for a child to pursue their higher secondary degree.
  • The artists donated their works to the Foundation because they believe that it is vectors like CryptoVerse Island , WISe.ART and Maiti Nepal which will raise awareness about forgotten or ignored drastic situations around the world.

Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe

Retrieved on: 
Tuesday, September 10, 2024

Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in 20 markets in Central and Eastern Europe.

Key Points: 
  • Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in 20 markets in Central and Eastern Europe.
  • Santhera Pharmaceuticals and GENESIS Pharma have signed a distribution agreement for 20 markets in Central and Eastern Europe.
  • “This distribution agreement with GENESIS Pharma marks a significant achievement for Santhera as we expand the global availability of AGAMREE.
  • In addition, patients who switched from a standard of care corticosteroid to AGAMREE maintained the efficacy benefit while recovering their growth and bone health.